Evidence map›Paper›PMID 42596850›Full record

ReviewInternational journal of oncology2026

The pivotal role of SCD1 in digestive cancers: Bridging lipid metabolic reprogramming and programmed cell death (Review).

Yangxi Fu, Zheng Wang, Lin Liu, Xudong Tang

Abstract readReview
In one paragraph

Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yangxi FuGraduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. China.
Zheng WangInstitute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, P.R. China.
Lin LiuInstitute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, P.R. China.
Xudong TangInstitute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stearoyl‑CoA desaturase‑1 (SCD1) has emerged as a critical nexus linking lipid metabolic reprogramming to the regulation of cell death. Frequently overexpressed in digestive system malignancies ‑ including gastric, liver and colorectal cancers ‑ SCD1 represents a promising therapeutic target. This review systematically examined how SCD1, through its lipid‑modifying functions, governs three key forms of regulated cell death ‑ ferroptosis, autophagy and apoptosis ‑ thereby driving malignant progression and mediating therapy resistance in digestive cancers. Building on this mechanistic framework, the specific contributions of these regulatory pathways to tumor biology and their association with drug resistance were delineated. Current preclinical therapeutic strategies targeting SCD1 were then highlighted, encompassing both monotherapy and combination approaches with ferroptosis inducers, chemotherapeutic agents or targeted drugs. Finally, key challenges and outline future directions for drug development and clinical translation in this rapidly evolving field were discussed.

Indexed as

Digestive System NeoplasmsLipid MetabolismStearoyl-CoA DesaturaseAnimalsAntineoplastic AgentsApoptosisAutophagyDrug Resistance, NeoplasmFerroptosisGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingAntineoplastic AgentsSCD protein, humanStearoyl-CoA Desaturaseapoptosisautophagydigestive cancersferroptosislipid metabolic reprogrammingstearoyl‑CoA desaturase‑1

Identifiers

PMID42596850
PMCPMC13496939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.